Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
February 2019, Vol 12, No 1, Supplement 2: Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
Treatment of acute bacterial skin and skin structure infections (ABSSSI) places a significant burden on the healthcare system, primarily due to expenditures associated with hospitalization costs. This publication details the results of a budget impact model study designed to estimate the potential annual budget impact of introducing omadacycline as a treatment option for patients with ABSSSI who present to the emergency department for care.
Improving the quality and safety of care in the inpatient and ambulatory settings is, indeed, a global quest. As part of this journey, I had the privilege of traveling to Kuala Lumpur, Malaysia, for the 35th Annual Meeting of the International Society for Quality in Health Care, known as ISQua.
Comparing the Medicaid Prospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies in 2015 and 2016
Lana T. Al-Omar, PharmD, BCPS, Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP, Amber D. Cizmic, PharmD, BCACP, Tara B. Vlasimsky, PharmD, BCPS, BCACP
Collaborative drug therapy management protocols are defined and written agreements between pharmacists and providers that allow pharmacists to optimize medication therapy management for individual patients.
Collaborative Efforts Help the Avoidance of Diabetes Mismanagement
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD, Gary Oderda, PharmD, MPH, Joseph Biskupiak, PhD, MBA, Douglas S. Burgoyne, PharmD, FAMCP, Steven G. Avey, RPh, MS, FAMCP, Steven R. Feldman, MD, PhD
Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis
Arijita Deb, PhD, Nilanjana Dwibedi, PhD, Traci LeMasters, PhD, Jo Ann Hornsby, MD, Wenhui Wei, PhD, Usha Sambamoorthi, PhD
Rheumatoid arthritis (RA) is a chronic systemic inflammatory condition that negatively affects the physical and mental health of individuals.
Comorbidities in Rheumatoid Arthritis Present Clinical, Economic Challenges for All Stakeholders
The 2018 midterm elections are a few months behind us, with the Democrats now in control of the House of Representatives and the Republicans maintaining their hold on the Senate. Hence, the future of the pharmaceutical industry—at least until the 2020 presidential election—is unclear.
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
Page 8 of 194
Results 71 - 80 of 1934
Results 71 - 80 of 1934